Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atypical energy-related symptoms define biologically distinct subtypes of major depressive disorder.

medRxiv : the preprint server for health sciences·2026
Same author

Identification of a Shiga toxin A-derived peptide internalized into Gb3 receptor-bearing cells via interaction with the Shiga toxin B subunit.

FEBS letters·2026
Same author

Supporting desistance from crime and recovery from drug use with a patient-facing bidirectional eHealth tool: a case report.

Journal of medical case reports·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

The Association of First Provider Seen With Time Loss From Work Among Workers With Back Injury: A Cohort Study.

American journal of industrial medicine·2026
Same author

The Swedish Twin Registry, a Research Database, in the Era of New Swedish Legislation.

Twin research and human genetics : the official journal of the International Society for Twin Studies·2026

Related Experiment Video

Updated: May 13, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Label-free kinetic binding data as a decisive element in drug discovery.

Karl Andersson1, Robert Karlsson, Stefan Löfås

  • 1Biacore AB, Rapsgatan 7 SE-75450 Uppsala, Sweden. stefan.lofas@biacore.com.

Expert Opinion on Drug Discovery
|March 19, 2013
PubMed
Summary

Drug discovery benefits from label-free kinetic binding data, moving beyond simple affinity. Optimizing association and dissociation rates refines compound selection for better drug-target and drug-ADME interactions.

More Related Videos

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

Related Experiment Videos

Last Updated: May 13, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

Area of Science:

  • Pharmacology
  • Biochemistry
  • Drug Discovery

Background:

  • Traditional drug discovery often relies on affinity, which can be misleading for drug potency.
  • Label-free kinetic binding data offers a more nuanced understanding of drug-target and drug-ADME-marker interactions.
  • Emerging technologies enable the acquisition of kinetic data crucial for drug development.

Purpose of the Study:

  • To review literature on compound selection in drug discovery, emphasizing kinetic data.
  • To highlight the importance of association and dissociation rates in drug-target interactions.
  • To explore the role of kinetic profiling in refining drug candidates early in the discovery process.

Main Methods:

  • Literature review of studies on kinetic-based binding data in drug discovery.
  • Analysis of the significance of association and dissociation rates in drug-protein interactions.
  • Examination of how kinetic properties influence compound selection strategies.

Main Results:

  • Kinetic data provides valuable insights beyond simple affinity for drug potency.
  • Optimizing both association and dissociation rates can yield compounds with improved kinetic profiles.
  • Considering kinetic properties of drug-ADME-marker interactions enhances compound quality.

Conclusions:

  • Kinetic data on drug-protein interactions is becoming essential in modern drug discovery.
  • Understanding and optimizing kinetic parameters are key to successful compound selection.
  • Label-free kinetic assays offer a powerful approach to advance drug development.